cardiac differentiation medium (stempro-34 sf Search Results


complete stempro™-34 medium  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc complete stempro™-34 medium
Complete Stempro™ 34 Medium, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/stempro/pmc11330481-101-22-24
Average 90 stars, based on 1 article reviews
complete stempro™-34 medium - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti-cd3 fitc  (Becton Dickinson)
90
Becton Dickinson anti-cd3 fitc
Anti Cd3 Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/anti+cd3/us09464139-1373-28-31
Average 90 stars, based on 1 article reviews
anti-cd3 fitc - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
stempro-34 sfm medium  (Corning Life Sciences)
90
Corning Life Sciences stempro-34 sfm medium
Stempro 34 Sfm Medium, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/stempro++34+sfm+complete+medium/pm37393719-35-6-14
Average 90 stars, based on 1 article reviews
stempro-34 sfm medium - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
stempro-34 sfm medium  (Biochrom)
90
Biochrom stempro-34 sfm medium
Stempro 34 Sfm Medium, supplied by Biochrom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/stempro+34+sfm+medium/pm30728213-118-0-9
Average 90 stars, based on 1 article reviews
stempro-34 sfm medium - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
stempro 34 medium  (Thermo Fisher)
93
Thermo Fisher stempro 34 medium
Stempro 34 Medium, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/Ethyl+oxamate%2C+99%25/pm39912384-228-8-10
Average 93 stars, based on 1 article reviews
stempro 34 medium - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
stempro™-34 slm  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc stempro™-34 slm
Stempro™ 34 Slm, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/stempro++34+slm/pm35334405-34-15-21
Average 90 stars, based on 1 article reviews
stempro™-34 slm - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
stempro 34 sfm  (Fisher Scientific)
86
Fisher Scientific stempro 34 sfm
Stempro 34 Sfm, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/34+sfm+stempro/pmc12992950-47-0-3
Average 86 stars, based on 1 article reviews
stempro 34 sfm - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
induction 3 medium i3m  (Thermo Fisher)
99
Thermo Fisher induction 3 medium i3m
Induction 3 Medium I3m, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/Transferrin/pm37230083-79-30-40
Average 99 stars, based on 1 article reviews
induction 3 medium i3m - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
anti-cd3-alexa 700  (Becton Dickinson)
90
Becton Dickinson anti-cd3-alexa 700
Phenotype analyses of elderly monkey PBMCs on days 0 (pre infection), 14 (acute phase), and at necropsy. (A) Gating schematics of T cell panel used to identify CD4+ and CD8+ T cells and memory subsets. Subsets analyzed were CD4+, CD8+, CD4+CD8+, and CD4−CD8− populations within <t>CD3+</t> gates. Further categorization was performed into central memory (CD28+CD95+), effector memory (CD28−CD95+), and naïve (CD28−CD95−) subsets. (B) Percentage loss of CD4+ and CD4+/CD8+ cells with days post infection relative to initial percentage of these cells calculated as (%CD4+ cell on day 14) × 100/(%CD4+ cells on day 0). (C) Percentage of CD4+, CD8+, CD4+CD8+ double-positive, and CD4−CD8− double-negative populations based on total <t>CD3+</t> cells. (D) Percentages of CD4+ and CD8+ memory subsets based on total CD4+ and CD8+ T cells, respectively. (E) Percentages of CD4+CD8+ and CD4−CD8− memory subsets based on total CD4+CD8+ and CD4−CD8− T cells, respectively. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; **P < 0.01; ns, not significant.
Anti Cd3 Alexa 700, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/human+foxp3+buffer+set/pmc10878093-385-5-9
Average 90 stars, based on 1 article reviews
anti-cd3-alexa 700 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
stempro 34 sfm  (Thermo Fisher)
99
Thermo Fisher stempro 34 sfm
Phenotype analyses of elderly monkey PBMCs on days 0 (pre infection), 14 (acute phase), and at necropsy. (A) Gating schematics of T cell panel used to identify CD4+ and CD8+ T cells and memory subsets. Subsets analyzed were CD4+, CD8+, CD4+CD8+, and CD4−CD8− populations within <t>CD3+</t> gates. Further categorization was performed into central memory (CD28+CD95+), effector memory (CD28−CD95+), and naïve (CD28−CD95−) subsets. (B) Percentage loss of CD4+ and CD4+/CD8+ cells with days post infection relative to initial percentage of these cells calculated as (%CD4+ cell on day 14) × 100/(%CD4+ cells on day 0). (C) Percentage of CD4+, CD8+, CD4+CD8+ double-positive, and CD4−CD8− double-negative populations based on total <t>CD3+</t> cells. (D) Percentages of CD4+ and CD8+ memory subsets based on total CD4+ and CD8+ T cells, respectively. (E) Percentages of CD4+CD8+ and CD4−CD8− memory subsets based on total CD4+CD8+ and CD4−CD8− T cells, respectively. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; **P < 0.01; ns, not significant.
Stempro 34 Sfm, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/D(%2B)-Glucose/pmc03591227-41-23-25
Average 99 stars, based on 1 article reviews
stempro 34 sfm - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
pseudomonas sp 34 e 7  (ATCC)
94
ATCC pseudomonas sp 34 e 7
Phenotype analyses of elderly monkey PBMCs on days 0 (pre infection), 14 (acute phase), and at necropsy. (A) Gating schematics of T cell panel used to identify CD4+ and CD8+ T cells and memory subsets. Subsets analyzed were CD4+, CD8+, CD4+CD8+, and CD4−CD8− populations within <t>CD3+</t> gates. Further categorization was performed into central memory (CD28+CD95+), effector memory (CD28−CD95+), and naïve (CD28−CD95−) subsets. (B) Percentage loss of CD4+ and CD4+/CD8+ cells with days post infection relative to initial percentage of these cells calculated as (%CD4+ cell on day 14) × 100/(%CD4+ cells on day 0). (C) Percentage of CD4+, CD8+, CD4+CD8+ double-positive, and CD4−CD8− double-negative populations based on total <t>CD3+</t> cells. (D) Percentages of CD4+ and CD8+ memory subsets based on total CD4+ and CD8+ T cells, respectively. (E) Percentages of CD4+CD8+ and CD4−CD8− memory subsets based on total CD4+CD8+ and CD4−CD8− T cells, respectively. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; **P < 0.01; ns, not significant.
Pseudomonas Sp 34 E 7, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/Pseudomonas+sp/us10655153-401-10-39
Average 94 stars, based on 1 article reviews
pseudomonas sp 34 e 7 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
stempro-34 medium  (AGC Inc)
90
AGC Inc stempro-34 medium
Phenotype analyses of elderly monkey PBMCs on days 0 (pre infection), 14 (acute phase), and at necropsy. (A) Gating schematics of T cell panel used to identify CD4+ and CD8+ T cells and memory subsets. Subsets analyzed were CD4+, CD8+, CD4+CD8+, and CD4−CD8− populations within <t>CD3+</t> gates. Further categorization was performed into central memory (CD28+CD95+), effector memory (CD28−CD95+), and naïve (CD28−CD95−) subsets. (B) Percentage loss of CD4+ and CD4+/CD8+ cells with days post infection relative to initial percentage of these cells calculated as (%CD4+ cell on day 14) × 100/(%CD4+ cells on day 0). (C) Percentage of CD4+, CD8+, CD4+CD8+ double-positive, and CD4−CD8− double-negative populations based on total <t>CD3+</t> cells. (D) Percentages of CD4+ and CD8+ memory subsets based on total CD4+ and CD8+ T cells, respectively. (E) Percentages of CD4+CD8+ and CD4−CD8− memory subsets based on total CD4+CD8+ and CD4−CD8− T cells, respectively. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; **P < 0.01; ns, not significant.
Stempro 34 Medium, supplied by AGC Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+differentiation+medium+(stempro-34+sf/stempro+34+medium/pmc07998227-126-27-19
Average 90 stars, based on 1 article reviews
stempro-34 medium - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Phenotype analyses of elderly monkey PBMCs on days 0 (pre infection), 14 (acute phase), and at necropsy. (A) Gating schematics of T cell panel used to identify CD4+ and CD8+ T cells and memory subsets. Subsets analyzed were CD4+, CD8+, CD4+CD8+, and CD4−CD8− populations within CD3+ gates. Further categorization was performed into central memory (CD28+CD95+), effector memory (CD28−CD95+), and naïve (CD28−CD95−) subsets. (B) Percentage loss of CD4+ and CD4+/CD8+ cells with days post infection relative to initial percentage of these cells calculated as (%CD4+ cell on day 14) × 100/(%CD4+ cells on day 0). (C) Percentage of CD4+, CD8+, CD4+CD8+ double-positive, and CD4−CD8− double-negative populations based on total CD3+ cells. (D) Percentages of CD4+ and CD8+ memory subsets based on total CD4+ and CD8+ T cells, respectively. (E) Percentages of CD4+CD8+ and CD4−CD8− memory subsets based on total CD4+CD8+ and CD4−CD8− T cells, respectively. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; **P < 0.01; ns, not significant.

Journal: Journal of Virology

Article Title: SHIV-C109p5 NHP induces rapid disease progression in elderly macaques with extensive GI viral replication

doi: 10.1128/jvi.01652-23

Figure Lengend Snippet: Phenotype analyses of elderly monkey PBMCs on days 0 (pre infection), 14 (acute phase), and at necropsy. (A) Gating schematics of T cell panel used to identify CD4+ and CD8+ T cells and memory subsets. Subsets analyzed were CD4+, CD8+, CD4+CD8+, and CD4−CD8− populations within CD3+ gates. Further categorization was performed into central memory (CD28+CD95+), effector memory (CD28−CD95+), and naïve (CD28−CD95−) subsets. (B) Percentage loss of CD4+ and CD4+/CD8+ cells with days post infection relative to initial percentage of these cells calculated as (%CD4+ cell on day 14) × 100/(%CD4+ cells on day 0). (C) Percentage of CD4+, CD8+, CD4+CD8+ double-positive, and CD4−CD8− double-negative populations based on total CD3+ cells. (D) Percentages of CD4+ and CD8+ memory subsets based on total CD4+ and CD8+ T cells, respectively. (E) Percentages of CD4+CD8+ and CD4−CD8− memory subsets based on total CD4+CD8+ and CD4−CD8− T cells, respectively. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; **P < 0.01; ns, not significant.

Article Snippet: Cells were then stained with surface anti-CD3-Alexa 700 (SP-34-2, BD Pharmingen), anti-CD4_V450 (L200, BD Horizon), anti-CD8a_BV650 (RPA-T8, BioLegend), CD95-PerCP_Cy5.5 (DX2, BD Pharmingen), anti-CD28_BV605 (28.2, BD Horizon), anti-CD69_BV711 (FN50, BD Horizon), anti-PD-1_PE-cy7 (EH12.2H7, BioLegend), and anti-HLA DR_PE-Texas Red (MHLDR17, Life Technologies).

Techniques: Infection

Analysis of myeloid and B cells on all five elderly monkey PBMCs from day 0 (pre infection), day 14 (acute phase), and necropsy. (A) Gating of myeloid and B cell populations. CD20−CD3−HLADR+ cells were gated for pDC and mDC, while the CD20+ cells were gated for mature and memory B cells. (B) Gating and percentages for pDC and mDC for all five elderly monkey for day 0 baseline, day 14, and necropsy. (C) Percentages of B cells gated on lymphocytes, monocytes gated on lymphocytes-monocytes, mDCs and pDCs gated on Lin−HLA-DR+ in all five elderly monkey. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; ns, not significant.

Journal: Journal of Virology

Article Title: SHIV-C109p5 NHP induces rapid disease progression in elderly macaques with extensive GI viral replication

doi: 10.1128/jvi.01652-23

Figure Lengend Snippet: Analysis of myeloid and B cells on all five elderly monkey PBMCs from day 0 (pre infection), day 14 (acute phase), and necropsy. (A) Gating of myeloid and B cell populations. CD20−CD3−HLADR+ cells were gated for pDC and mDC, while the CD20+ cells were gated for mature and memory B cells. (B) Gating and percentages for pDC and mDC for all five elderly monkey for day 0 baseline, day 14, and necropsy. (C) Percentages of B cells gated on lymphocytes, monocytes gated on lymphocytes-monocytes, mDCs and pDCs gated on Lin−HLA-DR+ in all five elderly monkey. Statistical differences between two groups (day 14 or necropsy vs day 0, or day 14 vs necropsy) were evaluated by the Wilcoxon matched-pairs signed rank test. The level of significance is indicated by P-values as follows: *P < 0.05; ns, not significant.

Article Snippet: Cells were then stained with surface anti-CD3-Alexa 700 (SP-34-2, BD Pharmingen), anti-CD4_V450 (L200, BD Horizon), anti-CD8a_BV650 (RPA-T8, BioLegend), CD95-PerCP_Cy5.5 (DX2, BD Pharmingen), anti-CD28_BV605 (28.2, BD Horizon), anti-CD69_BV711 (FN50, BD Horizon), anti-PD-1_PE-cy7 (EH12.2H7, BioLegend), and anti-HLA DR_PE-Texas Red (MHLDR17, Life Technologies).

Techniques: Infection